UNASSIGNED: Standard first-line therapy for @entity573 ( @entity573 ) consists of intravenous immunoglobulin (IVIG) and @entity117 . Current guidelines recommend 2 g/kg of IVIG and 80 to 100 mg/kg of @entity117 administered within the first 10 days of illness. This regimen has marked efficacy in preventing the development of @entity574 . Approximately 15% to 20% of treated @entity1 require a second dose of IVIG to control the inflammatory process. The role of adjunctive corticosteroid therapy with IVIG and @entity117 is evolving, with Japanese studies showing a clear benefit in those @entity1 at highest risk for development of @entity301 . The challenge in North America has been reliable identification of the highest-risk @entity1 , which still eludes us because the Japanese scoring systems are ineffective in multiethnic populations. Despite its efficacy, the precise mechanism of IVIG's effect in @entity573 is unclear but probably relates to its ability to down-regulate aspects of the up-regulated inflammatory response in @entity1 with @entity573 . [Pediatr Ann. 2017;46(1):e25-e28.].

Intravenous Immunoglobulin for the Treatment of XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity573 :: ('MESH:C537014', 'Disease') :: ['KD', 'Kawasaki disease'] @entity301 :: ('MESH:D003327', 'Disease') :: ['coronary disease'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity574 :: ('MESH:D003323', 'Disease') :: ['coronary artery aneurysms']
@entity573 :: (MESH:C537014,Disease) :: ['Kawasaki Disease']
